Asymptote Introduces The My.Cryochain Software Platform To Control The Cryogenic Cold Chain For Cellular Therapies
11/28/2016 9:24:59 AM
Enables standardization and audit of remote freezing and thawing
Cambridge UK, 28th November 2016: Asymptote Ltd. (Asymptote), specialists in cryochain
technology for advanced medicines, today announced the commercial launch of my.Cryochain, a
software platform developed specifically to give centralized control of the cryogenic cold chain for
As production of cellular therapies scales from clinical trials to market authorization and beyond,
manufacturing companies and research groups face multiple challenges. These include maintaining
consistency in freezing and thawing across multiple sites, and auditing remote processes, particularly
at the thawing stage. Asymptote developed my.Cryochain to provide a reliable and scalable solution
which can support Good Manufacturing Practice (GMP).
The new software synchronizes with Asymptote’s VIA Freeze range and soon-to-be released
automated thawing systems. Authorized users then have centralized control over the freezing and
thawing of cells; critical to the delivery of cell and gene therapies. Optimal freeze/thaw profiles can be
customized in the central system during process qualification. Once approved, they are synchronized
across all connected equipment, to remove variability and standardize processes.
my.Cryochain automatically manages profile versions to support continuous improvement. When a
process enhancement is identified, the history of all changes is automatically recorded and the new
profile is re-synchronized to all equipment in the field.
The my.Cryochain platform enables users to record, annotate and audit cryopreservation processes
electronically. The system provides instant and remote access to data from every VIA Freeze and
automated thawing system, thereby saving scientists’ time and increasing efficiency. A full electronic
audit trail also enables scientists to more easily identify anomalies and document observations. All
data is automatically stored in the central system, where it can be backed up and protected for five
years or more.
my.Cryochain has been developed as a scalable system to suit every stage of clinical development,
from early clinical trials and investigational work to mass production and delivery, with thousands of
connected VIA Freeze units and automated thawing systems across multiple continents.
Commenting on the commercial launch of my.Cryochain, John Morris, CEO, Asymptote said:
“We have developed my.Cryochain to enable cell therapy companies and scientists to have
centralized control over freezing and thawing of cellular therapies. The ability to define freeze/thaw
profiles centrally during process qualification and synchronize these to their VIA Freeze units and
automated thawing systems enables processes to be standardized across all sites. Real-time and
sustained access to data from the equipment, allows remote processes to be audited and
improvements made swiftly. For the first time, manufacturers and scientists will have control of the
end-to-end cryogenic cold chain.”
my.Cryochain is available now with options to securely host in the cloud or install on-premise, behind
a customer’s own firewall. For more information visit http://my.cryochain.com
my.Cryochain will be on display at the Asymptote stand, number 41, at the Cell Therapy
Manufacturing & Gene Therapy Congress, Amsterdam on 29 & 30 November 2016.
comments powered by